Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Up 5.8% in December

Structure Therapeutics Inc. (NASDAQ:GPCR) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 10,750,000 shares, a growth of 5.8% from the December 15th total of 10,160,000 shares. Currently, 19.8% of the shares of the company are sold short. Based on an average daily trading volume, of 824,600 shares, the short-interest ratio is presently 13.0 days.

Structure Therapeutics Trading Up 0.3 %

Shares of NASDAQ GPCR traded up $0.08 during midday trading on Friday, hitting $27.06. 846,835 shares of the company’s stock were exchanged, compared to its average volume of 770,004. The business’s fifty day moving average price is $30.78 and its two-hundred day moving average price is $36.03. The company has a market cap of $1.55 billion, a price-to-earnings ratio of -36.57 and a beta of -2.78. Structure Therapeutics has a 12-month low of $23.50 and a 12-month high of $62.74.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. JMP Securities reiterated a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Morgan Stanley began coverage on shares of Structure Therapeutics in a research report on Monday, September 23rd. They issued an “overweight” rating and a $118.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 target price on shares of Structure Therapeutics in a report on Monday, September 23rd. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $81.29.

Hedge Funds Weigh In On Structure Therapeutics

A number of institutional investors have recently made changes to their positions in GPCR. Wellington Management Group LLP boosted its stake in shares of Structure Therapeutics by 2.9% in the 3rd quarter. Wellington Management Group LLP now owns 7,769,771 shares of the company’s stock valued at $341,015,000 after purchasing an additional 221,851 shares in the last quarter. FMR LLC lifted its stake in shares of Structure Therapeutics by 6.7% in the 3rd quarter. FMR LLC now owns 6,128,444 shares of the company’s stock valued at $268,977,000 after acquiring an additional 383,635 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in Structure Therapeutics by 18.0% during the 3rd quarter. Janus Henderson Group PLC now owns 3,956,878 shares of the company’s stock valued at $173,623,000 after acquiring an additional 602,609 shares during the period. Driehaus Capital Management LLC grew its position in Structure Therapeutics by 3.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company’s stock worth $101,204,000 after acquiring an additional 86,833 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its stake in Structure Therapeutics by 196.5% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,238,268 shares of the company’s stock worth $54,348,000 after purchasing an additional 820,589 shares during the period. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.